Nuclear Imaging Devices Market

Nuclear Imaging Devices Market (Technology: Positron Emission Tomography (PET), Standalone PET Systems, Hybrid PET/CT Systems, Single-Photon Emission Computed Tomography (SPECT), Standalone SPECT Systems, Hybrid SPECT/CT Systems, Planar Scintigraphy; Product: SPECT Imaging Systems, Hybrid SPECT Imaging Systems, Standalone SPECT Imaging Systems, Hybrid PET Imaging Systems, Planar Scintigraphy Imaging Systems; Application: Oncology, Cardiology, Neurology, Other Applications; End-user: Hospitals, Diagnostic Imaging Centers, Academic & Research Centers, Other End Users) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032.

Market Outlook

The global nuclear imaging devices market is poised for significant expansion, driven by technological advancements and the rising prevalence of chronic diseases. The industry, valued at approximately $3.14 billion in 2024, is projected to reach a market size of $5.24 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.4% over the forecast period. The global nuclear imaging devices industry is experiencing significant growth supported by technology and the rising prevalence of chronic diseases. The trend shows increased demand for advanced imaging in diagnostics, particularly as cancer and cardiovascular diseases rise in incidence. Innovations such as artificial intelligence create better accuracy and efficiency in imaging. However, challenges such as high capital equipment costs and regulatory restrictions could restrain market growth. Emerging markets with improving health care infrastructure present opportunities for major industry players to leverage the growing demand for cutting-edge nuclear imaging technologies.

Market Driver

Increasing Prevalence of Chronic Diseases

The economy for nuclear imaging devices is flourishing due to the rising incidence of chronic conditions like cancer and cardiovascular disorders. This subsequent surge in the demand for accurate diagnostic equipment created a larger market because it is pertinent that diagnosis occurs as early as possible in order to have effective treatment planning. Diagnostic capabilities have witnessed further growth with the recent technological advances in imaging systems and radiotracers. For instance, the introduction of new hardware and software techniques utilized in SPECT imaging, and SPECT/CT imaging, have been proven beneficial for monitoring disease assessment and treatment responses. An additional pertinent example is that the Flyrcado diagnostic drug from GE HealthCare was granted marketing approval by the U.S. FDA, further demonstrating the industry’s advancement in diagnostic accuracy for coronary artery disease. Overall, these new developments indicate that the industry is growing at a very high pace, mainly due to innovative technological advancements and increasing investments in healthcare.

Technological Advancements in Imaging

The nuclear imaging industry is undergoing significant transformation, propelled by technological advancements and strategic investments. Hybrid imaging systems, such as PET/CT and SPECT/CT, are enhancing diagnostic precision, particularly in oncology, thereby increasing their adoption across various clinical applications. The development of novel radiotracers, like Gallium-68, has further improved tumor detection capabilities, boosting the market share of precision imaging solutions. Artificial intelligence (AI) is revolutionizing imaging analysis by optimizing workflows and enhancing efficiency, aligning with current industry trends. For instance, Jones Radiology recently introduced South Australia’s first digital PET/CT scanner, the Omni Legend 32, offering clearer images with reduced radiation doses, thus improving patient safety and comfort. Additionally, the U.S. FDA approved GE HealthCare’s diagnostic drug, Flyrcado, for detecting coronary artery disease, reflecting a commitment to innovation in imaging agents. These developments underscore a robust growth trajectory for the nuclear imaging sector, positioning it as a pivotal component in the future of medical diagnostics.Healthcare Investment and Modernization

Rising healthcare expenditures globally are further propelling the adoption of nuclear imaging devices. Countries such as China and India are modernizing healthcare infrastructure, establishing diagnostic imaging centers, and prioritizing access to cutting-edge medical technology. These investments are expanding diagnostic capabilities, making advanced nuclear imaging solutions increasingly accessible to emerging markets.

Restraint for market

High Costs of Equipment

One of the primary challenges facing the nuclear imaging devices market is the high cost of equipment. These advanced imaging systems, such as PET scanners, can cost upwards of $2 million, which makes them out of reach for many healthcare facilities, particularly smaller hospitals or clinics in developing regions. The capital investment required to purchase and maintain these devices is a significant barrier, limiting their availability and accessibility in underserved areas. In addition to the initial purchase price, the operational and maintenance costs associated with nuclear imaging equipment further exacerbate financial constraints. This often results in a disparity in healthcare quality, where only large, well-funded medical centers can afford the latest imaging technology.

Opportunities for Market Growth

Expansion in Emerging Markets

The global nuclear imaging market holds exciting growth potential, especially in emerging markets like India and Brazil, where healthcare infrastructure is rapidly evolving. As these countries invest in modernizing their healthcare systems, the demand for advanced diagnostic tools such as nuclear imaging devices is expected to soar. This presents a golden opportunity for manufacturers to tap into new markets and establish a strong foothold in regions with growing healthcare needs.

Integration of AI and Digital Technologies

Another transformative opportunity lies in the integration of artificial intelligence (AI) and digital technologies into nuclear imaging workflows. AI has the potential to revolutionize the way diagnostic imaging is analyzed, offering unprecedented accuracy, speed, and operational efficiency. Companies that develop AI-powered applications for image analysis are positioned to streamline diagnostic processes, reduce human error, and ultimately improve patient outcomes. A great example of this trend is GE Healthcare’s strategic acquisition of MIM Software, aiming to enhance its medical imaging analysis capabilities through AI solutions.

As digitalization continues to shape the future of healthcare, the nuclear imaging sector is poised for innovation. Manufacturers who embrace AI and digital technologies will not only stay ahead of the competition but also contribute to the evolution of healthcare by offering cutting-edge solutions that improve the quality of patient care and diagnostic accuracy. This is a market ripe with potential for those ready to invest and innovate.

Possibly the fastest growing market in the imaging device business or imaging systems is nuclear medicine. Advancements in technology and utilization of investments make it possible for innovations to open up new avenues for improvement in diagnostic effectiveness and patient convenience through AI-enabled solutions or by introducing a new line of wearable imaging systems. Strategic acquisitions like the one by Siemens of Advanced Accelerator Applications (AAA) and Duke Street’s acquisition of Agito Medical will also open up new market share, igniting growth in the industry. Market initiatives such as China long-term nuclear medicine plan and U.S. Medicare reimbursement reforms extend patient access to advanced imaging technologies for further market growth. Upgrade of healthcare facilities across the globe is going to cut down the turnaround time and indirectly boost nuclear medicine infrastructure. Growth in the use of radiopharmaceuticals and theranostics is driving personalized medicine.

The trends and future aspects of the industry show an unceasing bullish in this market as driven by technological innovations, regulatory support, and increased demand for advanced diagnostics solutions.

China: Rapid Growth and Government Support

China is heavily investing in nuclear medicine, with over 3.9 million patients served annually and nearly 13,000 staff members.
The Mid- and Long-Term Development Plan for Medical Isotopes aims to double the market by 2035, covering all high-grade hospitals.
Domestic manufacturing of PET/CT scanners is increasing, reducing reliance on imports.
Theranostics adoption is expanding, driven by National Medical Products Administration approvals.

India: Rising Demand and Infrastructure Expansion

HCG Cancer Centre in Bengaluru has upgraded its PET/CT scanner to accommodate growing oncology patients.
The PLI Scheme for Medical Devices saw ₹8,039.63 crore in sales and ₹3,844.01 crore in exports, boosting domestic manufacturing.
High patient demand and limited R&D investments remain key challenges.

North America (USA & Canada): Technology Advancements and Policy Changes

Nova Scotia’s first 3D nuclear medicine scanner (StarGuide SPECT/CT) enhances patient outcomes.
GE HealthCare’s Omni Legend PET/CT scanner is now being manufactured in the USA for AI-powered molecular imaging.
CMS policy changes will now separately reimburse radiopharmaceuticals over $630, improving patient access to nuclear imaging.
West Virginia University developed a wearable PET scanner (AMPET) for real-time motion-compatible brain imaging.

Europe: Market Growth and Private Investments

Duke Street acquired Agito Medical, targeting Europe’s $545M medical imaging rental market, expected to grow 7% annually.
San Pietro Fatebenefratelli Hospital in Italy installed a Total-Body PET/CT scanner for research and early diagnosis.
Mediso unveiled the AnyScan® TRIO SPECT/CT at the European Association of Nuclear Medicine (EANM) for theranostics imaging.
Positrigo secured EU clearance for its NeuroLF brain PET system to diagnose neurodegenerative diseases.

UK: Advancements in Imaging and Workforce Challenges

Royal Shrewsbury Hospital’s £3.6M gamma camera investment improves nuclear medicine capabilities and attracts specialized staff.
Serac Imaging Systems developed Seracam, a portable gamma camera for real-time imaging in operating rooms and ICUs.
Long wait times for imaging exams highlight a radiologist shortage, increasing reliance on AI-driven imaging solutions.

Global M&A and Investment Trends

Siemens Healthineers completed a $223M acquisition of Novartis’ imaging unit (Advanced Accelerator Applications), expanding PET radiopharmaceuticals production.
WORK Medical Technology Group partnered with Chartwell Medical to expand global imaging investments and acquisitions.

Competitive Landscape

GE Healthcare

Siemens Healthineers

Lantheus Medical Imaging

Bayer

Curium

Bracco Imaging

Jubilant DraxImage

PharmaLogic Holdings

Eczacibasi-Monrol Nuclear Products

Nordion

Fujifilm Holdings Corporation

Canon Medical Systems Corporation

Philips Healthcare

Digirad Corporation

Neusoft Medical Systems Co., Ltd.

Recent Advances

In September 2024, Siemens Healthineers has purchased Novartis’s nuclear diagnostics imaging business for $223 million to expand its PET radiopharmaceuticals business into Europe. Enlitic Inc., a software company, plans to purchase Laitek for an expected purchase price of $5 million which will include proprietary ability or trade secrets. Patientpay mergers with ClearGage while Check Point Software will acquire capabilities for advanced threat prevention from Cyberint. Actuality of these acquisitions is that they are being aligned with the customers’ experience in order to achieve the expected financial goals of healthcare organizations.
In October 2024, NorthStar Medical Radioisotopes invests in a Contract Development & Manufacturing (CDMO) facility that produces and develops medical radioisotopes specifically for applications in cancer treatment. This space covers 52,000 square feet and seeks to address a critical gap in the availability of specialized skills and facilities within biopharma companies. NorthStar remains the only US company that co-locates commercial scale multi-radioisotope production with radiopharmaceutical manufacturing. The global market for radiopharmaceuticals is expected to experience an average annual growth rate of 8.8%, reaching a total worth of $11.4 billion by 2032.
In June 2024, Bristol Myers Squibb which recently acquired RayzeBio at the cost of $4.1 billion has paused the phase 3 study of cancer drug RYZ101 because of a shortage of a critical radioactive isotope which is actinium. This isotope is one of the rarest and will be needed for the therapy, which is currently being tested for neuroendocrine tumors. BMS expects patient enrollment in the new trial to be ready for the third quarter this year and anticipates supporting ongoing clinical supply by the first quarter of 2024. The actinium shortage calls into question supply chain considerations for radiopharmaceuticals, with some insisting the industry enjoys the benefit of strategic ties. However, former CEO of RayzeBio, Ken Song, remains optimistic that there will be a brighter future for the use of radiopharmaceuticals, arguing that the actinium isotope supply should increase therefore reducing historical barriers to discovery and development.
In June 2024, Lantheus, a leading radiopharma company, has acquired global rights to two novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers. The deal, announced on June 27, includes global rights to the radiotheranostic pair for an upfront payment of $35 million and potential regulatory milestone payments plus royalties. The deal demonstrates Lantheus’s dedication to pioneering cancer care and marks a significant step towards addressing unmet medical needs in prostate and breast cancer treatment. The agreement includes global rights to the radiotheranostic pair and potential regulatory milestone payments plus royalties. Lantheus plans to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025.
In April 2024, MIM is GE HealthCare’s third acquisition as an independent company, after acquiring imaging company IMACTIS in 2023 and the company Caption Health, which specializes in AI-based ultrasound applications. Chicago-based GE HealthCare has acquired MIM Software, a company specializing in AI and imaging solutions, thus adding to its digital imaging portfolio. MIM Software supplies remote software solutions in the disciplines of oncology, nuclear medicine, cardiac imaging, and neuroimaging. The company intends to automate many tasks, thereby permitting users to focus on caregiving for cancer. The products of MIM Software will be marketed under the GE HealthCare label, including MIM SurePlan, MIM Symphony, and MIM Maestro. The acquisition is in keeping with GE HealthCare’s precision care strategy of personalizing care, improving hospital efficiencies, and enhancing clinician effectiveness.

Market Segmentation

Segmentation by Technology

Positron Emission Tomography (PET)
- Standalone PET Systems
- Hybrid PET/CT Systems
Single-Photon Emission Computed Tomography (SPECT)
- Standalone SPECT Systems
- Hybrid SPECT/CT Systems
Planar Scintigraphy

Segmentation by Product

SPECT Imaging Systems
- Hybrid SPECT Imaging Systems
- Standalone SPECT Imaging Systems
Hybrid PET Imaging Systems
Planar Scintigraphy Imaging Systems

Segmentation by Application

Oncology
Cardiology
Neurology
Other Applications

Segmentation by End User

Hospitals
Diagnostic Imaging Centers
Academic & Research Centers
Other End Users

FAQ

What is driving the growth of the nuclear imaging device market?

The market is expanding due to technological advancements, rising chronic disease prevalence, government policies, and increased healthcare infrastructure investments.

What are the key technologies in nuclear imaging?

The main technologies include Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Hybrid PET/CT and SPECT/CT systems, and Planar Scintigraphy.

Which applications are nuclear imaging devices used for?

These devices are primarily used in oncology, cardiology, neurology, and other medical applications for accurate diagnostics and treatment planning.

What are the major market restraints?

The high cost of equipment, including purchase, maintenance, and operational expenses, limits accessibility, especially in smaller hospitals and developing regions.

What opportunities exist in the market?

Expansion in emerging markets (India, Brazil) and AI integration in imaging workflows present significant growth opportunities.

How is AI transforming nuclear imaging?

AI enhances diagnostic accuracy, speeds up image analysis, reduces human error, and improves patient outcomes through automated workflows.

Which regions are leading in nuclear imaging advancements?

China, the USA, Europe, and India are making major strides with government support, facility upgrades, and new imaging technologies.

What are the key industry trends?

Trends include wearable PET scanners, theranostics, AI-powered imaging, and increased investment in radiopharmaceuticals.

Who are the major players in the nuclear imaging device market?

Leading companies include GE Healthcare, Siemens Healthineers, Philips Healthcare, Lantheus Medical Imaging, Curium, Bracco Imaging, and Canon Medical Systems.

What is the future outlook for the market?

With continued technological innovation, strategic mergers, and increased healthcare investments, the market is set for steady growth in the coming years.

Table Of Content

1. Executive Summary

1.1. Definition

1.2. Research Scope

1.3. Key Findings by Major Segments

2. Global Nuclear Imaging Devices Market Overview

2.1. Nuclear Imaging Devices Market Dynamics

2.1.1. Drivers

2.1.2. Opportunities

2.1.3. Restraints

2.1.4. Challenges

2.2. Product Analysis

2.3. Technological Advancements

2.4. Key Industry Updates

2.5. Key Insights on the Nuclear Imaging Installed Base

3. Global Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

3.1. Global Nuclear Imaging Devices Market Analysis, 2021-2023

3.2. Global Nuclear Imaging Devices Market Opportunity and Forecast, 2025-2032

3.3. Global Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

3.3.1. Global Nuclear Imaging Devices Market Analysis by Technology: Introduction

3.3.2. Market Trend, Analysis and Forecast, By Technology, 2021-2032

3.3.2.1. Positron Emission Tomography (PET)

3.3.2.1.1. Standalone PET Systems

3.3.2.1.2. Hybrid PET/CT Systems

3.3.2.2. Single-Photon Emission Computed Tomography (SPECT)

3.3.2.2.1. Standalone SPECT Systems

3.3.2.2.2. Hybrid SPECT/CT Systems

3.3.2.3. Planar Scintigraphy

3.4. Global Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

3.4.1. Global Nuclear Imaging Devices Market Analysis by Product: Introduction

3.4.2. Market Trend, Analysis and Forecast, By Product, 2021-2032

3.4.2.1. SPECT Imaging Systems

3.4.2.2. Hybrid PET Imaging Systems

3.4.2.3. Planar Scintigraphy Imaging Systems

3.5. Global Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

3.5.1. Global Nuclear Imaging Devices Market Analysis by Application: Introduction

3.5.2. Market Trend, Analysis and Forecast, By Application, 2021-2032

3.5.2.1. Oncology

3.5.2.2. Cardiology

3.5.2.3. Neurology

3.5.2.4. Other

3.6. Global Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

3.6.1. Global Nuclear Imaging Devices Market Analysis by End-user: Introduction

3.6.2. Market Trend, Analysis and Forecast, By End-user, 2021-2032

3.6.2.1. Hospital

3.6.2.2. Diagnostic Imaging Centers

3.6.2.3. Academic & Research Centers

3.7. Global Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Region, 2021-2032

3.7.1. Global Nuclear Imaging Devices Market Analysis by Region : Introduction

3.7.2. Market Trend, Analysis and Forecast, By Region , 2021-2032

3.7.2.1. North America

3.7.2.2. Europe

3.7.2.4. APAC

3.7.2.5. Latin America

3.7.2.6. Middle East & Africa

4. North America Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

4.1. North America Nuclear Imaging Devices Market Analysis, 2021-2023

4.2. North America Nuclear Imaging Devices Market Opportunity and Forecast, 2025-2032

4.3. North America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

4.3.1. Positron Emission Tomography (PET)

4.3.1.1. Standalone PET Systems

4.3.1.2. Hybrid PET/CT Systems

4.3.2. Single-Photon Emission Computed Tomography (SPECT)

4.3.2.1. Standalone SPECT Systems

4.3.2.2. Hybrid SPECT/CT Systems

4.3.3. Planar Scintigraphy

4.4. North America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

4.4.1. SPECT Imaging Systems

4.4.2. Hybrid PET Imaging Systems

4.4.3. Planar Scintigraphy Imaging Systems

4.5. North America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

4.5.1. Oncology

4.5.2. Cardiology

4.5.3. Neurology

4.5.4. Others

4.6. North America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

4.6.1. Hospital

4.6.2. Diagnostic Imaging Centers

4.6.3. Academic & Research Centers

4.7. North America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Country, 2021-2032

4.7.1. U.S.

4.7.2. Canada

5. Europe Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

5.1. Europe Nuclear Imaging Devices Market Analysis, 2021-2023

5.2. Europe Nuclear Imaging Devices Market Opportunity and Forecast, 2025-2032

5.3. Europe Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

5.3.1. Positron Emission Tomography (PET)

5.3.1.1. Standalone PET Systems

5.3.1.2. Hybrid PET/CT Systems

5.3.2. Single-Photon Emission Computed Tomography (SPECT)

5.3.2.1. Standalone SPECT Systems

5.3.2.2. Hybrid SPECT/CT Systems

5.3.3. Planar Scintigraphy

5.4. Europe Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

5.4.1. SPECT Imaging Systems

5.4.2. Hybrid PET Imaging Systems

5.4.3. Planar Scintigraphy Imaging Systems

5.5. Europe Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

5.5.1. Oncology

5.5.2. Cardiology

5.5.3. Neurology

5.5.4. Others

5.6. Europe Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

5.6.1. Hospital

5.6.2. Diagnostic Imaging Centers

5.6.3. Academic & Research Centers

5.7. Europe Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Country, 2021-2032

5.7.1. Germany

5.7.2. UK

5.7.3. France

5.7.4. Spain

5.7.5. Italy

5.7.6. Denmark

5.7.7. Rest of Europe

6. Asia Pacific Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

6.1. Asia Pacific Nuclear Imaging Devices Market Analysis, 2021-2023

6.2. Asia Pacific Nuclear Imaging Devices Market Opportunity and Forecast, 2026-2032

6.3. Asia Pacific Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

6.3.1. Positron Emission Tomography (PET)

6.3.1.1. Standalone PET Systems

6.3.1.2. Hybrid PET/CT Systems

6.3.2. Single-Photon Emission Computed Tomography (SPECT)

6.3.2.1. Standalone SPECT Systems

6.3.2.2. Hybrid SPECT/CT Systems

6.3.3. Planar Scintigraphy

6.4. Asia Pacific Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

6.4.1. SPECT Imaging Systems

6.4.2. Hybrid PET Imaging Systems

6.4.3. Planar Scintigraphy Imaging Systems

6.5. Asia Pacific Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

6.5.1. Oncology

6.5.2. Cardiology

6.5.3. Neurology

6.5.4. Others

6.6. Asia Pacific Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

6.6.1. Hospital

6.6.2. Diagnostic Imaging Centers

6.6.3. Academic & Research Centers

6.7. Asia Pacific Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Country, 2021-2032

6.7.1. China

6.7.2. Japan

6.7.3. India

6.7.4. Australia & New Zealand

6.7.5. South Korea

6.7.6. Singapore

6.7.7. Rest of Asia Pacific

7. Latin America Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

7.1. Latin America Nuclear Imaging Devices Market Analysis, 2021-2023

7.2. Latin America Nuclear Imaging Devices Market Opportunity and Forecast, 2027-2032

7.3. Latin America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

7.3.1. Positron Emission Tomography (PET)

7.3.1.1. Standalone PET Systems

7.3.1.2. Hybrid PET/CT Systems

7.3.2. Single-Photon Emission Computed Tomography (SPECT)

7.3.2.1. Standalone SPECT Systems

7.3.2.2. Hybrid SPECT/CT Systems

7.3.3. Planar Scintigraphy

7.4. Latin America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

7.4.1. SPECT Imaging Systems

7.4.2. Hybrid PET Imaging Systems

7.4.3. Planar Scintigraphy Imaging Systems

7.5. Latin America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

7.5.1. Oncology

7.5.2. Cardiology

7.5.3. Neurology

7.5.4. Others

7.6. Latin America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

7.6.1. Hospital

7.6.2. Diagnostic Imaging Centers

7.6.3. Academic & Research Centers

7.7. Latin America Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Country, 2021-2032

7.7.1. Brazil

7.7.2. Mexico

7.7.3. Colombia

7.7.4. Rest of Latin America

8. Middle East & Africa Nuclear Imaging Devices Market Outlook and Future Prospects, 2021-2032

8.1. Middle East & Africa Nuclear Imaging Devices Market Analysis, 2021-2023

8.2. Middle East & Africa Nuclear Imaging Devices Market Opportunity and Forecast, 2028-2032

8.3. Middle East & Africa Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Technology, 2021-2032

8.3.1. Positron Emission Tomography (PET)

8.3.1.1. Standalone PET Systems

8.3.1.2. Hybrid PET/CT Systems

8.3.2. Single-Photon Emission Computed Tomography (SPECT)

8.3.2.1. Standalone SPECT Systems

8.3.2.2. Hybrid SPECT/CT Systems

8.3.3. Planar Scintigraphy

8.4. Middle East & Africa Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Product, 2021-2032

8.4.1. SPECT Imaging Systems

8.4.2. Hybrid PET Imaging Systems

8.4.3. Planar Scintigraphy Imaging Systems

8.5. Middle East & Africa Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Application, 2021-2032

8.5.1. Oncology

8.5.2. Cardiology

8.5.3. Neurology

8.5.4. Others

8.6. Middle East & Africa Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By End-user, 2021-2032

8.6.1. Hospital

8.6.2. Diagnostic Imaging Centers

8.6.3. Academic & Research Centers

8.7. Middle East & Africa Nuclear Imaging Devices Market Analysis, Opportunity and Forecast, By Country, 2021-2032

8.7.1. GCC Countries

8.7.2. South Africa

8.7.3. Rest of Middle East & Africa

9. Global Nuclear Imaging Devices Market Competitive Landscape, Market Share Analysis, and Company Profiles

9.1. Nuclear Imaging Devices Market Share Analysis, By Company (2024)

9.2. Company Profiles

1. GE Healthcare

Company Overview

Financial Highlights

Product Portfolio

SWOT Analysis